Last reviewed · How we verify

NCT06104748

A Cohort of Maternal Vascular Malperfusion-related FGR (CoMVMFGR)

Recruiting now Last updated 7 June 2024
What this trial tests

trial in MVM-FGR in 500 participants. Currently enrolling.

Timeline
10 August 2023
Primary endpoint
30 December 2025
30 December 2025

Quick facts

Lead sponsorShanghai First Maternity and Infant Hospital
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment500
Start date10 August 2023
Primary completion30 December 2025
Estimated completion30 December 2025
Sites1 location across China

Conditions studied

Sponsor

Shanghai First Maternity and Infant Hospital

Who can join

Adults 18 to 45, female only, with MVM-FGR. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Based on a precise diagnostic standard process, through a multicenter study, we will establish a cohort focusing on placenta-mediated fetal growth restriction (FGR). Long-term follow-up will be conducted to seek predictive indicators for short-term and long-term adverse outcomes of maternal vascular malperfusion-related FGR (MVM-FGR).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Shanghai First Maternity and Infant Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06104748.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing